Multiple drug resistance mediated by P-glycoprotein is not a major factor in a slow response to therapy in childhood all

Pediatric Hematology and Oncology

Volumn 15, Issue 1, 1998, Pages 11-21

  Kanerva, Jukka ^a   Türikainen, Maarit ^b   Mäkipernaa, Anne ^c   Riikonen, Pekka ^d   Möttönen, Merja ^e   Salmi, Toivo T ^f   Krusius, Tom ^b   Saarinen Pihkala, Ulla M ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b FINNISH RED CROSS BLOOD SERVICE   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF OULU   (Finland)

^f UNIVERSITY OF TURKU   (Finland)

Author keywords

Childhood; Leukemia; Multiple drug resistance; P glycoprotein

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; GLYCOPROTEIN P; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTRATHECAL DRUG ADMINISTRATION; LYMPHOBLAST; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; T CELL LEUKEMIA; TREATMENT OUTCOME;

EID: 0031882229     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.3109/08880019809009504     Document Type: Article

References (24)

1. Margolin JF, Poplack DG. Acute lymphoblastic leukemia. In: Pizzo P, Poplack D, eds. Principles and Practice in Pediatric Oncology. Philadelphia: JB Lippincott; 1997:409-462.
2. Miller D, Coccia P, Bleyer W. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from Childrens Cancer Study Group. J Clin Oncol. 1989;7:1807-1815.
3. Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood. 1993;81:2215-2222. Editorial.
4. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385-427.
5. Del Poeta G, Stasi R, Aronica G, et al. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood. 1996;87:1997-2004.
6. Goasguen JE, Dossot JM, Fardel O, et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood. 1993;81:2394-2398.
7. Sauerbrey A, Zintl F, Volm M. P-glycoprotein and glutathione S-transferase pi in childhood acute lymphoblastic leukaemia. Br J Cancer. 1994;70:1144-1149.
8. Pieters R, Hongo T, Loonen AH, et al. Different types of non-P-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukaemia. Br J Cancer. 1992;65:691-697.
9. Pieters R, Kaspers GJ, Klumper E, Veerman AJ. Clinical relevance of in vitro drug resistance testing in childhood acute lymphoblastic leukemia: the state of the art. Med Pediatr Oncol. 1994;22:299-308.
10. Ubezio P, Limonta M, D'Incalci M, et al. Failure to detect the P-glycoprotein multidrug resistant phenotype in cases of resistant childhood acute lymphocytic leukaemia. Eur J Cancer Clin Oncol. 1990;25:1895-1899.
11. Miller DR, Leikin S, Albo V, Sather H, Hammond D. Prognostic importance of morphology (FAB classification) in childhood acute lymphoblastic leukaemia (ALL). Br J Haematol. 1981;48:199-206.
12. Tiirikainen M. Evaluation of red blood cell lysing solutions for the detection of intracellular antigens by flow cytometry. Cytometry. 1995;20:341-348.
13. Tiirikainen MI, Syrjälä MT, Jansson SE, Krusius T. Flow cytometric analysis of P-glycoprotein in normal and leukemic cells. Ann Hematol. 1992;65:124-130.
14. Chan HS, DeBoer G, Haddad G, Gallie BL, Ling V. Multidrug resistance in pediatric malignancies. Hematol Oncol Clin North Am. 1995;9:275-318.
15. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesmann MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues Proc Natl Acad Sci USA. 1987;84:265-269.
16. O'Meara A, Imamura A, Johnson P, et al. Reactivity of P-glycoprotein monoclonal antibodies in childhood cancers. Oncology. 1992;49:203-208.
17. Xie XY, Robb D, Chow S, Hedley DW. Discordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia. Leukemia 1995;9:1882-1887.
18. Tafuri A, Sommaggio A, Burba L, et al. Prognostic value of rhodamine-efflux and MDR-1/P-170 expression in childhood acute leukemia. Leuk Res. 1995;19:927-931.
19. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 1996;56:3010-3020.
20. Scheper RJ, Bulte JWM, Brakkee JGP, et al. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance. Int J Cancer. 1988;42:389-394.
21. Lehne G, De Angelis P, Clausen OP, Egeland T, Tsuruo T, Rugstad HE. Binding diversity of antibodies against external and internal epitopes of the multidrug resistance gene product P-glycoprotein. Cytometry. 1995;20:228-237.
22. Campos L, Guyotat E, Archimbaud E. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood. 1992;79:473-476.
23. Ludescher C, Eisterer W, Hilbe W, et al. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia. Leukemia. 1995;9:350-356.
24. Brophy NA, Marie JP, Rojas VA, et al. Mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: a critical evaluation by four techniques. Leukemia. 1994;8:327-335.